泊沙康唑治疗侵袭性真菌病研究进展
The research progress of Posaconazole in invasive fungal infection
摘要
2006年美国食品药品管理局（FDA）批准上市的新型抗真菌药物——泊沙康唑（Posaconazole）。其化学结构与伊曲康唑同源，通过抑制麦角固醇的生物合成而发挥其抗真菌活性，具有抗菌谱广、生物利用度高、耐受性好等特征。
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2012年第2期154-157,共4页
Chinese Journal of Practical Internal Medicine
关键词
侵袭性真菌病
抗真菌药
泊沙康唑
invasive fungal infection
antifungal agents
Posaconazole
参考文献21
-
1Pfaller, Messer et al. In vitro activities of posaconazole ( Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans [ J ]. Antimicrob Agents Chemother,2001,45( 10) :2862 - 2864.
-
2Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voricon- azole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program [ J ]. Diagn Microbial Infect Dis, 2004,48 ( 3 ) : 201 - 205.
-
3Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posacon- azole ,fluconazole, itraconazole, voriconazole, and arnphotericin B a- gainst a large collection of clinically important molds and yeasts [J]. Antimicrob Agents Chemother,2006,50(6) :2009 -2015.
-
4Pfaller MA, Messer SA, Boyken L, et al. Global trends in the anti- fungal susceptibility of Cryptococcus neoformans ( 1990 to 2004 ) [ J]. J Clirt Microbiol,2005,43 ( 5 ) :2163 - 2167.
-
5Espinel-Ingroff. In vitro antifungal activities of anidulafungin and micafungin,licensed agents and the investigational triazole posacon- azole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature [ J ]. Rev Iberoam Micol,2003,20 (4) :121 - 136.
-
6Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of posaconazole,itraconazole, voriconazole, amphotericin B, and flucon- azole against 37 clinical isolates of zygomycetes [ J ]. Antimicrob A- gents Chemother,2002,46 (5) : 1581 - 1582.
-
7Gilgado F, Serena C, Cano J, et al. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex [ J ]. Antimicrob A- gents Chemother,2006,50 (12) :4211 - 4213.
-
8Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults [ J ]. Antimicrob Agents Chemother ,2003,47 (9) :2788 -2795.
-
9Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting heahhy men [ J ]. Antimicrob Agents Chemother, 2004,48 ( 3 ) : 804 - 808.
-
10Vazquez GA, Skiest D J, Nieto L, et al. A multicenter randomized trial envaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects With HIV/AIDS [ J]. Clin hffect Dis,2006,42 ( 8 ) : 1179 - 1186.
-
1王睿.泊沙康唑[J].中华结核和呼吸杂志,2015,38(6):441-442.
-
2徐宵寒,张路,段明辉.评价泊沙康唑预防血液系统疾病患者粒细胞缺乏期侵袭性真菌病的效果[J].中国感染控制杂志,2017,16(1):32-35. 被引量：4
-
3王彩娟,谢单丹.抗真菌药 泊沙康唑(posaconazole)[J].世界临床药物,2007,28(8):509-509.
-
4钱远宇,黎檀实,孟庆义.抗真菌药物联合治疗深部真菌感染的临床应用[J].中国实用内科杂志,2008,28(8):694-696. 被引量：5
-
5刘晓荻（译）,孙瑛（编）.泊沙康唑对难治性球孢子菌病有效[J].基础医学与临床,2007,27(12).
-
6泊沙康唑对难治性侵袭性曲菌病治疗有效[J].中华医学信息导报,2007,22(2):8-8.
-
7刘晓平,胡春.泊沙康唑(posaconazole)[J].中国药物化学杂志,2007,17(4):266-267. 被引量：4
-
8荣蓉,吴斌.深部真菌感染药物治疗进展[J].内科,2006,1(1):45-47. 被引量：4
-
9魏宇宁.泊沙康唑与氟康唑或伊曲康唑预防治疗中性粒细胞减少症的比较[J].国外医学（药学分册）,2007,34(3):235-236. 被引量：2
-
10FDA批准抗真菌新药泊沙康唑（posaconazole）[J].中国新药杂志,2007,16(6):465-465.
